License and Collaboration Agreements (Tables)

12 Months Ended

Dec. 31, 2018

Organization Consolidation And Presentation Of Financial Statements [Abstract]

License, Collaboration and Other Revenue

In accordance with our collaboration agreements, we recognized license, collaboration and other revenue as follows (in thousands):

		Year Ended December 31,
Partner	Agreement	2018		2017		2016
Bristol-Myers Squibb	NKTR-214	$	1,059,768	$	—		—
Baxalta Incorporated / Takeda	Hemophilia, including ADYNOVATE® and ADYNOVITM		20,328		11,443		650
Eli Lilly and Company	NKTR-358		11,634		130,087		—
Amgen, Inc.	Neulasta®		5,000		5,000		5,000
Ophthotech Corporation(1)	Fovista®		—		19,123		1,408
Bayer Healthcare LLC(1)	BAY41-6551 (Amikacin Inhale)		—		17,931		1,429
AstraZeneca AB	MOVANTIK® and MOVENTIG®		—		4,600		33,000
Other			535		22,781		18,895
License, collaboration and other revenue		$	1,097,265	$	210,965	$	60,382

(1) These collaboration agreements were completed as of December 31, 2017.

Changes in Deferred Revenue Balance from Collaboration Agreements

The following table presents the changes in our deferred revenue balance from our collaboration agreements during the year ended December 31, 2018 (in thousands):

	For the year ended December 31, 2018
Deferred revenue—December 31, 2017	$	37,970
Transition adjustment related to adoption of ASC 606		(1,953	)
Additions to deferred revenue		5,950
Recognition of previously unearned revenue		(17,331	)
Deferred revenue—December 31, 2018	$	24,636